Table 1 Baseline demographics and clinical characteristics (FAS)
Placebo (n = 100) | Eptinezumab 100 mg (n = 90) | Total (N = 190) | |
|---|---|---|---|
Sex, n (%) | |||
Male | 18 (18.0) | 24 (26.7) | 42 (22.1) |
Female | 82 (82.0) | 66 (73.3) | 148 (77.9) |
Age, median (interquartile range) | 43.5 (35–52) | 43.5 (37–54) | 43.5 (35–52) |
Region, n (%) | |||
Asia | 81 (81.0) | 74 (82.2) | 155 (81.6) |
Europe | 19 (19.0) | 16 (17.8) | 35 (18.4) |
Baseline characteristics, days (SD) | |||
Mean MMDs | 19.7 (3.8) | 19.5 (3.6) | 19.6 (3.7) |
Mean MHDs | 20.9 (3.3) | 20.6 (2.9) | 20.8 (3.2) |
Mean AHM use (days) | 18.9 (4.5) | 19.2 (4.6) | 19.1 (4.6) |
Baseline mean MMDs with use of AHM | 19.2 (4.0) | 18.9 (3.8) | 19.1 (3.9) |
Previous preventive treatment failures, n (%) | |||
Amitriptyline | 15 (15.0) | 12 (13.3) | 27 (14.2) |
Botulinum toxin A | 13 (13.0) | 10 (11.1) | 23 (12.1) |
Candesartan | 2 (2.0) | 0 (0.0) | 2 (1.1) |
Divalproex | 1 (1.0) | 1 (1.1) | 2 (1.1) |
Flunarizine | 20 (20.0) | 15 (16.7) | 35 (18.4) |
Metoprolol | 4 (4.0) | 3 (3.3) | 7 (3.7) |
Propranolol | 10 (10.0) | 9 (10.0) | 19 (10.0) |
Topiramate | 20 (20.0) | 16 (17.8) | 36 (18.9) |
Valproate | 3 (3.0) | 3 (3.3) | 6 (3.2) |
Other | 24 (24.0) | 18 (20.0) | 42 (22.1) |